Meu SciELO
Serviços Personalizados
Journal
Artigo
Indicadores
Citado por SciELO
Acessos
Links relacionados
Citado por Google
Similares em SciELO
Similares em Google
Compartilhar
Revista Española de Enfermedades Digestivas
versão impressa ISSN 1130-0108
Resumo
RODRIGO, L. et al. Retreatment and maintenance therapy with infliximab in fistulizing Crohn' disease. Rev. esp. enferm. dig. [online]. 2004, vol.96, n.8, pp.548-558. ISSN 1130-0108.
Objectives: infliximab has clearly demonstrated its efficacy in the short-term treatment of fistulizing Crohn' disease. We present here the results of retreatment and long-term maintenance therapy. Patients and methods: eighty one consecutive patients with active fistulizing Crohn' disease, in whom previous treatments had failed, were treated with infliximab. All patients received as the initial treatment of 5 mg/kg i.v. infusions (weeks 0, 2, and 6). Those patients who failed to respond after the initial cycle (group 1, n= 25), or those who relapsed after having responded (group 2, n=13), received retreatment with three similar doses (weeks 0,2, and 6). Those who responded to retreatment were included in a long-term maintenance programme (n=44), with repeated doses (5 mg/kg i.v. infusions) every eight weeks for 1-2 years. Results: in the initial treatment 56% of the patients responded partially; this response being complete in 44%. In the retreatment, 28% of group 1 (non-responders) presented a complete response, compared to 77% in group 2 (relapsers) (p< 0.0001). In the maintenance treatment, the global response was 88% (39/44). The mean number of doses per patient was 4.4 ± 2 (range 1-9) with a duration of 36 ± 12 weeks (range 8-72). Adverse effects were not significantly increased in either treatment. Conclusions: both retreatment and long-term maintenance therapy with infliximab, are highly effective and well tolerated in fistulizing Crohn' disease patients.
Palavras-chave : Retreatment; Maintenance therapy; Infliximab; Fistulizing Crohn' disease.